Clinical trials: Healthy Females
Contraception
Study on Safety and Efficacy of an Oral Contraceptive in Long Cycles
The purpose of the study is to determine safety and efficacy of long-cycle regimens of an oral contraceptive.
- Trial name
- NCT00266032
- Testing
- Flexible (extended) treatment of EE20/DRSP (YAZ, BAY86-5300), Fixed extended treatment of EE20/DRSP (YAZ, BAY86-5300), Standard 24+4 treatment of EE20/DRSP (YAZ, BAY86-5300)
- Where
- 35 sites in Canada, Germany and 1 more
- Volunteers
- 1,166 people, healthy volunteers welcome
- Sponsor
- Bayer
Drug-Drug Interaction Healthy Volunteers
A Drug-Drug Interaction Study to Evaluate the Effect of Vapendavir on the Pharmacokinetics of Midazolam in Healthy Male and Female Volunteers
The primary aim of this Phase 1 study is to evaluate the effect of vapendavir daily doses of 528 mg daily (QD) and 264 mg twice daily (BID) on the pharmacokinetic (PK) profile of midazolam, a cytochrome (CYP) 3A4 substrate.
- Trial name
- NCT02204501
- Testing
- Midazolam 5mg Syrup, Vapendavir 264 mg BID, Vapendavir 528 mg QD
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Biota Scientific Management Pty Ltd
Postmenopausal Symptoms
Pharmacokinetic Evaluation of Brisdelle™ (Formerly Known as Mesafem) Following Single & Repeat Oral Administration in Healthy Postmenopausal Women
The purpose of this study is to assess the pharmacokinetics (absorption, breakdown and elimination from the body), safety and tolerability of Brisdelle (paroxetine mesylate) Capsules 7.5 mg when given as a single dose and…
- Trial name
- N30-005 (NCT01829919)
- Testing
- Brisdelle (paroxetine mesylate)
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Noven Therapeutics
Pharmacokinetics, Therapeutic Equivalency
Bioequivalence Study of the Oral Contraceptive (OC) Tablet Containing Norgestimate (NGM)/Ethinyl Estradiol (EE) With or Without Folic Acid in Healthy Women.
The purpose of the study is to determine the bioequivalence of Norgestimate (NGM) and Ethinyl Estradiol (EE) in 2 formulations of 250 mcg NGM/25 mcg EE, 1 without folic acid and 1 containing 400 mcg folic acid.
- Conditions
- Pharmacokinetics, Therapeutic Equivalency, Contraceptives, Oral
- Trial name
- NCT00709644
- Testing
- Norgestimate; Ethinyl Estradiol; Folic acid.
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Kidney Failure, Chronic, End-Stage Kidney Disease
A Study to Evaluate the Effect of MK-5684 in Male Participants With Severe Renal Impairment (RI) and With End-stage Renal Disease (ESRD) (MK-5684-010)
The goal of the study is to learn what happens to levels of MK-5684 in people with severe renal impairment and end-stage renal disease versus a healthy person's body over time.
- Conditions
- Kidney Failure, Chronic, End-Stage Kidney Disease, Renal Failure, Chronic, Renal Failure, End-Stage
- Trial name
- NCT06814132
- Testing
- MK-5684, Prednisone, Fludrocortisone acetate
- Where
- 2 sites in United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Healthy
Influence of Pramipexole on the QT Interval of the ECG in Healthy Male and Female Volunteers
The objective of the study is to assess that pramipexole does not prolong the QT interval more than placebo
- Trial name
- NCT02262546
- Testing
- Pramipexole extended-release (ER) tablets, Pramipexole immediate-release (IR) tablets, Moxifloxacin
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy Female Adults
A Study of Navlimetostat (BMS-986504) Drug Interactions and Food Effect in Healthy Participants
The purpose of this study is to assess the food effect and drug interactions on drug levels of Navlimetostat in health adult female participants
- Trial name
- NCT07800897
- Testing
- Navlimetostat, Itraconazole, Rifampin
- Where
- Canada
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Healthy Volunteer
A Study to Evaluate the Bioavailability and Food Effects of Oral Venetoclax New Tablet Formulation 2.0 in Healthy Adult Female Participants
The objective of this study is to assess the bioavailability (BA) of venetoclax new high drug load hot melt extrusion-03 (HME-03) tablet formulation at two different tablet strengths relative to the commercial venetoclax tablet…
- Trial name
- NCT06742086
- Testing
- Venetoclax
- Where
- 2 sites in United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- AbbVie
Osteoporosis
Safety and Tolerability of Odanacatib (0822-059)
This study will test the weighted average inhibition of u-NTx/Cre (aminoterminal crosslinked telopeptide of Type 1 collagen) and AUC (0-168 hours) of Odanacatib
- Trial name
- NCT01068262
- Testing
- Odanacatib
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Recurrent Genital Herpes Simplex Type 2
A Study to Assess the Safety, Pharmacokinetics, and Antiviral Activity of ABI-5366 in Healthy Participants and Participants Seropositive for HSV-2 With Recurrent Genital Herpes
This study is designed to assess safety, tolerability, and pharmacokinetics (PK) of single ascending dose (SAD) of ABI-5366 in Part A in healthy participants and multiple-ascending doses (MAD) of ABI-5366 in Part B in…
- Trial name
- NCT06385327
- Testing
- ABI-5366
- Where
- 15 sites in Australia, New Zealand
- Volunteers
- 115 people, healthy volunteers welcome
- Sponsor
- Assembly Biosciences
Growth and Development
To Investigate the Impact of a Nutritional Supplement on Bone Turnover Markers in Indian Healthy Premenopausal Women (25- 45 Years) After 6 Months of Intervention
To investigate the effect of nutritional supplement on bone turnover markers (which are sensitive and respond quickly to nutrition or drug intervention) in Indian healthy premenopausal women after 6 months of intervention.
- Trial name
- NCT03155269
- Testing
- Fortified Beverage Powder, Non fortified beverage Powder
- Where
- India
- Volunteers
- 114 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy
Study to Determine the Ability of Seresis to Act as a Skin Protection Agent in Healthy Young Female Volunteers
Study to detect the efficacy of Seresis® in reducing the damage produced on the skin by Matrix-metalloproteinases (MMP) and by oxidative stress (marker: heme oxygenase-1 expression) activated by UV radiation
- Trial name
- NCT02191813
- Testing
- Seresis®
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy
A Safety, Tolerability, PD and PK Study in Healthy Adults
The primary objective of this study is to evaluate the safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of TRV734 given as a single dose (Part A) and as multiple ascending doses (Part B) in healthy subjects.
- Trial name
- NCT02211625
- Testing
- Open-label TRV734 125 mg, TRV734 blinded, Oxycodone IR 10 mg
- Where
- United States
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Trevena Inc.
Healthy, Renal Insufficiency
Study of Pirtobrutinib (LOXO-305) in Participants With Impaired Kidney Function and Healthy Participants
The main purpose of this study is to measure how much of pirtobrutinib (LOXO-305) gets into the bloodstream and how long it takes the body to eliminate it in participants with impaired kidney function and healthy participants.
- Trial name
- NCT06190678
- Testing
- Pirtobrutinib
- Where
- 5 sites in United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Vulvovaginal Atrophy, Vasomotor Symptoms
A Phase 1, Open-Label, Parallel Group Study to Evaluate the Pharmacokinetics and Safety of DARE-HRT1 in Healthy PostMenopausal Women
An open-label study to assess the PK of estradiol, estrone and progesterone from the DARE-HRT1 intravaginal rings at two different dose strengths.
- Trial name
- NCT05418426
- Testing
- IVR Dose 1, IVR Dose 2, Oral Reference
- Where
- 2 sites in Australia
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Daré Bioscience, Inc.
Pulmonary Disease, Chronic Obstructive
Endotoxin Challenge Study For Healthy Men and Women
The proposed study will examine the effect of pre-treatment with inhaled GSK256066 using a lung inflammation model induced by bronchoscopic instillation of bacterial endotoxin (lipopolysaccharide, LPS) in healthy volunteers.Data…
- Trial name
- NCT00515268
- Testing
- GSK256066
- Where
- Germany
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis
A Study in Healthy Volunteers to Evaluate the Drug-Drug Interaction Potential of CCX168 With Concomitant Medications
The primary objective of this study will be to evaluate the drug-drug interaction potential of CCX168 with concomitant medications, as either a perpetrator or a victim, following oral administration of CCX168 to healthy…
- Trial name
- NCT06004947
- Testing
- CCX168, Midazolam, Celecoxib
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Amgen
Parkinson's Disease
Pharmacokinetic Properties of Rasagiline (Lu 00-773) in Healthy Young Chinese Men and Women
The purpose of this study is to fulfil regulatory requirements for registration of a new chemical entity in China. Rasagiline is approved for the treatment of Parkinson's Disease (PD) in Europe and the US.
- Trial name
- NCT01652313
- Testing
- Rasagiline
- Where
- China
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- H. Lundbeck A/S
Healthy
A Study in Healthy Men and Women to Find Out How Well Different Doses of BI 1291583 Are Tolerated
The main objectives of this trial are to investigate safety, tolerability and pharmacokinetics (PK) of BI 1291583 in healthy male and female subjects following oral administration of multiple rising doses over 4 weeks.
- Trial name
- NCT03868540
- Testing
- BI 1291583
- Where
- Germany
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy Volunteers, Polycystic Kidney, Autosomal Dominant
Effect of Venglustat in Patients With Renal Impairment
Primary Objective: To study the effect of mild, moderate and severe renal impairment on the pharmacokinetics (PK) of Venglustat following a single dose.
- Trial name
- NCT03687554
- Testing
- Venglustat GZ/SAR402671
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Genzyme, a Sanofi Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.